Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment
Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globall...
Saved in:
| Published in | International journal of pharmaceutics: X Vol. 10; p. 100362 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.12.2025
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H2S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn2+ to form nanozymes (5-ASA-Zn2+, A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H2S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting via CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H2S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD.
Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment. [Display omitted] |
|---|---|
| AbstractList | Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H
S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn
to form nanozymes (5-ASA-Zn
, A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H
S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting
CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H
S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD. Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H2S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn2+ to form nanozymes (5-ASA-Zn2+, A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H2S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting via CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H2S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD. Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H2S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn2+ to form nanozymes (5-ASA-Zn2+, A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H2S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting via CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H2S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD. Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment. [Display omitted] Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H2S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn2+ to form nanozymes (5-ASA-Zn2+, A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H2S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting via CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H2S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD.Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H2S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn2+ to form nanozymes (5-ASA-Zn2+, A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H2S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting via CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H2S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD. Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition. The rising incidence of IBD is placing pressure on healthcare systems globally. Although the precise etiology remains elusive, the dysregulation between reactive oxygen species (ROS) and hydrogen sulfide (H 2 S) is a crucial determinant in the pathogenesis of inflammatory bowel disease (IBD). Though 5-aminosalicylic acid (5-ASA) is effective in the early-stage of IBD, restoring intestinal environmental balance, its use is limited by off-target problem and toxicity. This study introduces a novel oral nano-drug delivery system that improves efficacy and reduces side effects by coordinating 5-ASA with Zn 2+ to form nanozymes (5-ASA-Zn 2+ , A-Z) and encapsulating them in nanoplatform (A-Z@cHP), which made from chitosan (CS), hyaluronic acid (HA), pectin (PC) and calcium chloride. The nanozymes displayed uniform particle size, stability, and ability to regulate ROS and H 2 S. The nanoplatform showed the characteristic of acid resistance, pectinase responsive drug release, low cytotoxicity, and effective targeting via CD44 receptors. In a DSS-induced mouse colitis model, A-Z@cHP significantly improved body weight, disease activity index, colon length, and colonic barrier while reducing inflammation by restoring the balance of ROS and H 2 S. Furthermore, the balance restoration of intestinal flora also benefits from the above regulatory effect of nanoparticles. Biosafety evaluations confirmed no significant side effects. In conclusion, this targeted nanoplatform provides a promising new approach for improving the efficacy of 5-ASA against IBD. Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment. Unlabelled Image |
| ArticleNumber | 100362 |
| Author | Zou, Jiafeng Wang, Yanwen Fang, Siqi Chen, Xinyi Qi, Chendong Lin, Yiting Lu, Jing Zhao, Xinlin Ji, Qingdong Li, Xiang Zheng, Shuhui Gao, Feng |
| Author_xml | – sequence: 1 givenname: Yiting surname: Lin fullname: Lin, Yiting organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 2 givenname: Siqi surname: Fang fullname: Fang, Siqi organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 3 givenname: Xinyi surname: Chen fullname: Chen, Xinyi organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 4 givenname: Xiang surname: Li fullname: Li, Xiang organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 5 givenname: Xinlin surname: Zhao fullname: Zhao, Xinlin organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 6 givenname: Yanwen surname: Wang fullname: Wang, Yanwen organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 7 givenname: Jing surname: Lu fullname: Lu, Jing organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 8 givenname: Qingdong surname: Ji fullname: Ji, Qingdong organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 9 givenname: Shuhui surname: Zheng fullname: Zheng, Shuhui organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 10 givenname: Jiafeng surname: Zou fullname: Zou, Jiafeng organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China – sequence: 11 givenname: Chendong surname: Qi fullname: Qi, Chendong email: chendong.qi@shgh.cn organization: Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 12 givenname: Feng surname: Gao fullname: Gao, Feng email: fgao@ecust.edu.cn organization: Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40747109$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstuEzEUhkeoiJbSF2CBvGST4Mt4ZiwhIVRxqVQJFrC2Tuzj4GjGDrYTSJ-GR8XplKrdIPkm-z_fsY__581JiAGb5iWjS0ZZ92az9Jvt7yWnXNYNKjr-pDnjUtEFk11_8mB92lzkvKGUcs6oGNSz5rSlfdszqs6aP1_RFB8gI0mYtzFkv0cSIMTtCMXFNJE6kJhgJAXSGgtaYnGsqnQgcgGTDzHD6M2hdgLGWwLBkhsfDDExJlvhxcdAbKox4RZ9c5iQ-FCbG2GaoMTKWsVfOBLrMx4vUxJCmTCUF81TB2PGi7v5vPn-8cO3y8-L6y-fri7fXy-MUJQvHFNu4IZ3sJJuUNz1vW2FbJ0VwkHHDbOdAyV6aq2VvbG05UxSy8wgHEcqzpurmWsjbPQ2-QnSQUfw-nYjprWGVLwZUfdgBDOuR6V4yxQb5GC5BUqNVW7VYmW9m1nb3WpCa-ozav0eQR-fBP9Dr-NeMy4Yp11XCa_vCCn-3GEuevLZ4DhCwLjLWnAh67t7qar01cNk91n-_XEV8FlgUsw5obuXMKqPXtIbffSSPnpJz16qQW_nIKw133tMOhuPwaD1qTqmFsX_L_wvDprW3g |
| Cites_doi | 10.1016/j.ijbiomac.2021.02.186 10.2174/1874467212666190308103448 10.1002/adhm.202401869 10.1016/j.carbpol.2021.118013 10.1016/j.ijpharm.2023.122741 10.1002/smll.202207350 10.4062/biomolther.2020.227 10.1021/acsnano.3c10541 10.2147/JIR.S304101 10.1155/2023/4613842 10.1021/acsami.3c03255 10.1155/2018/7918261 10.1021/acsami.3c02128 10.1016/j.ijpharm.2024.124117 10.1002/adma.202004647 10.1038/s41385-018-0086-4 10.1021/acs.langmuir.1c03118 10.3390/biomedicines11092466 10.3390/ijms20020398 10.1016/j.saa.2013.01.021 10.1016/j.actbio.2024.01.015 10.1371/journal.pone.0268551 10.3389/fimmu.2023.1143526 10.1002/pen.25479 10.1021/acsami.3c11594 10.3390/jfb16010024 10.1038/s41591-023-02217-7 10.1016/j.jsps.2024.102099 10.1016/j.cej.2023.144595 10.3389/fphar.2023.1260134 10.1080/14712598.2019.1666101 10.1080/19768354.2025.2451408 10.3389/fmicb.2022.817591 10.1053/j.gastro.2023.11.136 10.1016/j.jconrel.2024.07.071 10.1093/ibd/izae081 10.7150/jca.35375 10.3390/ph18010067 10.3390/ijms222312729 10.1016/j.jconrel.2023.08.011 10.1002/smll.201903473 10.1136/gutjnl-2024-332205 |
| ContentType | Journal Article |
| Copyright | 2025 2025 Published by Elsevier B.V. 2025 Published by Elsevier B.V. 2025 |
| Copyright_xml | – notice: 2025 – notice: 2025 Published by Elsevier B.V. – notice: 2025 Published by Elsevier B.V. 2025 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ijpx.2025.100362 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2590-1567 |
| ExternalDocumentID | oai_doaj_org_article_7ac31cf7e9924191858d2da00cd9fb4e PMC12312066 40747109 10_1016_j_ijpx_2025_100362 S2590156725000477 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 53G 6I. AAEDW AAFTH AALRI AAXUO AAYWO ABMAC ADVLN AEXQZ AFJKZ AFTJW AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS EJD FDB GROUPED_DOAJ HYE M41 OK1 ROL RPM SSZ AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c3902-f19f82c26ab5f892f77d4354fd33fa62c1d6fa9370ddd57cd042150d1c83f2e03 |
| IEDL.DBID | DOA |
| ISSN | 2590-1567 |
| IngestDate | Wed Aug 27 01:31:08 EDT 2025 Thu Aug 21 18:33:45 EDT 2025 Fri Aug 01 18:24:31 EDT 2025 Mon Aug 04 01:31:10 EDT 2025 Wed Aug 27 16:27:25 EDT 2025 Sat Aug 23 17:12:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Inflammatory bowel disease Pectin Zinc coordination driven nanozyme Chitosan Hyaluronic acid 5-aminosalicylic acid |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2025 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3902-f19f82c26ab5f892f77d4354fd33fa62c1d6fa9370ddd57cd042150d1c83f2e03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally. |
| OpenAccessLink | https://doaj.org/article/7ac31cf7e9924191858d2da00cd9fb4e |
| PMID | 40747109 |
| PQID | 3235390759 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7ac31cf7e9924191858d2da00cd9fb4e pubmedcentral_primary_oai_pubmedcentral_nih_gov_12312066 proquest_miscellaneous_3235390759 pubmed_primary_40747109 crossref_primary_10_1016_j_ijpx_2025_100362 elsevier_sciencedirect_doi_10_1016_j_ijpx_2025_100362 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-12-01 |
| PublicationDateYYYYMMDD | 2025-12-01 |
| PublicationDate_xml | – month: 12 year: 2025 text: 2025-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | International journal of pharmaceutics: X |
| PublicationTitleAlternate | Int J Pharm X |
| PublicationYear | 2025 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Yang, Ge, Tan, Liu, Yang, Liu, Zhang, Zhang, Liu, Shi, Wang, Li (bb0185) 2024; 374 Chen, Lin, Shi, Guo, Xu, Niu (bb0020) 2023; 471 Zhao, Huang, Xie, Liu, Liu, Wei, Wang, Zhang, Yuan, Wu, Ding, Long (bb0205) 2023; 15 Cheng, Zou, He, Hou, Wang, Xu, Yuan, Lan, Yang, Chen, Gao (bb0030) 2024; 367 Makhezer, Ben Khemis, Liu, Khichane, Marzaioli, Tlili, Mojallali, Pintard, Letteron, Nedelec, Benna, Marie, Sannier, Pelletier, Dang (bb0110) 2019; 12 Zou, Sun, He, Chen, Cheng, Xia, Ma, Zheng, Fu, Yuan, Lan, Lou, Chen, Gao (bb0220) 2023; 15 Tao, An, Lin, Tian, Yang (bb0160) 2019; 15 Zheng, Chen, Wang, Peng, Zhao, Xie, Li, Lin, Zhao, Ji, Tang, Liao (bb0210) 2024; 18 Sun, Zhang, Xiang, Cao, Yu (bb0155) 2022; 38 Hou, Li, Wang, Ma, Qin (bb0060) 2023; 14 Wang, Yu, Yang (bb0170) 2021; 14 Lemos, de Souza, Fajardo (bb0095) 2021; 265 Lv, Ren, Yao, Zou, Fang, Wang, Lan, Zhao, Gao (bb0105) 2023; 635 Chen, Feng, Chen, Xia, Yao, Ding, Li, Fu, Zheng, Ma, Zou, Lan, Gao (bb0025) 2024; 659 Le Berre, Roda, Nedeljkovic Protic, Danese, Peyrin-Biroulet (bb0090) 2019; 20 Al Asmari, Al Shehri, Khan, Al Omani, Kadasah, Horaib, Al Buraidi, Al Sharif, Mohammed, Abbasmanthiri, Osman (bb0010) 2023; 2023 Zou, Jiang, Chen, Ma, Xia, Ding, Yao, Lin, Chen, Zhao, Gao (bb0225) 2024; 13 Huang, Yang, Zhu, Chen, Zhao, Xiao, Wang, Song, Jiang, Yang, Zhang, Xiao, Nan, Wu, Ai (bb0065) 2023; 19 Parvin, Joo, Mandal (bb0140) 2025; 16 Lin, Piao, Zhao, Liao, Wang, Zhang, Liu (bb0100) 2025; 18 Dudzińska, Gryzinska, Ognik, Kulik, Kocki (bb0045) 2018; 2018 Adeyi, Ajisebiola, Adeyi, Adekunle, Akande, James, Ajayi, Yusuf, Idowu (bb0005) 2021; 25 Jhundoo, Siefen, Liang, Schmidt, Lokhnauth, Moulari, Béduneau, Pellequer, Larsen, Lamprecht (bb0075) 2021; 29 Török, Almási, Valkusz, Pósa, Varga, Kupai (bb0165) 2021; 22 Iglesias, Galbis, Blanco, Lucas, Benito, Paz (bb0070) 2019; 20 Marotti, Xu, Michalowski, Zhang, Domingues, Ameraoui, Moreels, Baatsen, Van Hul, Muccioli, Cani, Alhouayek, Malfanti, Beloqui (bb0115) 2024; 32 Karmi, Sun, Festen, Vich Vila, Gacesa, Weersma (bb0080) 2024; 73 Yang, He, Wang, Liang, Zhang, Tan, Tao, Wu, Dong, Zheng, Zhang, Feng, Cheng, Chen, Wei (bb0180) 2023; 14 Pallio (bb0130) 2023; 11 Chang, Hou, Jin, Zhou, Wang, Wang, Shu, Ding, Li, Lin (bb0015) 2020; 32 Xu, Zhu, Sun, Li, Wu, Hu (bb0175) 2023; 15 Moens, Muller, Bouwens (bb0125) 2022; 17 Yüksel, Voragen, Kort (bb0200) 2024; 21-23 Zou, Yuan, Chen, Chen, Yao, Chen, Li, Chen, Ding, Xia, Zhao, Gao (bb0230) 2024; 19 Gorospe, Windsor, Hracs, Coward, Buie, Quan, Caplan, Markovinovic, Cummings, Goddard, Williamson, Abbey, Abreu, Ali, Abdullah, Altuwaijri, Ahuja, Balderramo, Banerjee, Benchimol, Bernstein, Mas, Burisch, Chong, Dotan, Dutta, El Ouali, Forbes, Forss, Gearry, Dao, Hartono, Hilmi, Banos, Kaibullayeva, Kelly, Kotze, Lakatos, Lees, Limsrivilai, Loftus, Ludvigsson, Mak, Ng, Olen, Panaccione, Paudel, Quaresma, Rubin, Simadibrata, Sun, Suzuki, Toro, Turner, Vergara, Wei, Furusho, Yang, Ng, Kaplan (bb0050) 2024; 166 Ham, Park, Bae, Yeo, Jung (bb0055) 2025; 29 Soliman, Mohamed (bb0150) 2013; 107 Kim, Bang, Kim, Choi, Heo, Shim, Lee (bb0085) 2022; 13 Mehta, Mayers, Zhang, Bhosle, Glasser, Nguyen, Ma, Bae, Branck, Song, Sebastian, Pacheco, Seo, Clish, Paganon, Ananthakrishnan, Franzosa, Balskus, Chan, Huttenhower (bb0120) 2023; 29 Park, Kim, Kim, Jeong, Jung (bb0135) 2019; 12 Yue, Zuo, Bu, Zhu, Chen, Ma, Ma, Guo, Wen, Zhang, Hu, Wang, Yao, Chen, Wang, Pan, Wang, Liu (bb0195) 2020; 11 Ciorba, Konnikova, Hirota, Lucchetta, Turner, Slavin, Johnson, Condray, Hong, Cressall, Pizarro, Lorenzo, Heller, Moss, Swantek, Garrett (bb0040) 2024; 30 Yue, Jin, Chi, Yang, Lei, Zhu, Zhao (bb0190) 2020; 60 Shnaikat, Shakya, Bardaweel (bb0145) 2024; 32 Chung, Shin, Lee, Park, Han, Rhee, Cho, Hong, Lee (bb0035) 2021; 178 Zhong, Yang, Xu, Qian, Huang, Long, Qi, He, Zhang, Li, Hai, Wang, Zhao, Ye (bb0215) 2024; 177 Karmi (10.1016/j.ijpx.2025.100362_bb0080) 2024; 73 Zhong (10.1016/j.ijpx.2025.100362_bb0215) 2024; 177 Soliman (10.1016/j.ijpx.2025.100362_bb0150) 2013; 107 Zou (10.1016/j.ijpx.2025.100362_bb0230) 2024; 19 Dudzińska (10.1016/j.ijpx.2025.100362_bb0045) 2018; 2018 Ham (10.1016/j.ijpx.2025.100362_bb0055) 2025; 29 Park (10.1016/j.ijpx.2025.100362_bb0135) 2019; 12 Yue (10.1016/j.ijpx.2025.100362_bb0190) 2020; 60 Le Berre (10.1016/j.ijpx.2025.100362_bb0090) 2019; 20 Chang (10.1016/j.ijpx.2025.100362_bb0015) 2020; 32 Cheng (10.1016/j.ijpx.2025.100362_bb0030) 2024; 367 Chen (10.1016/j.ijpx.2025.100362_bb0020) 2023; 471 Gorospe (10.1016/j.ijpx.2025.100362_bb0050) 2024; 166 Lemos (10.1016/j.ijpx.2025.100362_bb0095) 2021; 265 Pallio (10.1016/j.ijpx.2025.100362_bb0130) 2023; 11 Chen (10.1016/j.ijpx.2025.100362_bb0025) 2024; 659 Xu (10.1016/j.ijpx.2025.100362_bb0175) 2023; 15 Yüksel (10.1016/j.ijpx.2025.100362_bb0200) 2024; 21-23 Makhezer (10.1016/j.ijpx.2025.100362_bb0110) 2019; 12 Shnaikat (10.1016/j.ijpx.2025.100362_bb0145) 2024; 32 Iglesias (10.1016/j.ijpx.2025.100362_bb0070) 2019; 20 Zou (10.1016/j.ijpx.2025.100362_bb0220) 2023; 15 Zou (10.1016/j.ijpx.2025.100362_bb0225) 2024; 13 Zhao (10.1016/j.ijpx.2025.100362_bb0205) 2023; 15 Ciorba (10.1016/j.ijpx.2025.100362_bb0040) 2024; 30 Al Asmari (10.1016/j.ijpx.2025.100362_bb0010) 2023; 2023 Jhundoo (10.1016/j.ijpx.2025.100362_bb0075) 2021; 29 Tao (10.1016/j.ijpx.2025.100362_bb0160) 2019; 15 Hou (10.1016/j.ijpx.2025.100362_bb0060) 2023; 14 Marotti (10.1016/j.ijpx.2025.100362_bb0115) 2024; 32 Mehta (10.1016/j.ijpx.2025.100362_bb0120) 2023; 29 Parvin (10.1016/j.ijpx.2025.100362_bb0140) 2025; 16 Zheng (10.1016/j.ijpx.2025.100362_bb0210) 2024; 18 Yue (10.1016/j.ijpx.2025.100362_bb0195) 2020; 11 Chung (10.1016/j.ijpx.2025.100362_bb0035) 2021; 178 Huang (10.1016/j.ijpx.2025.100362_bb0065) 2023; 19 Yang (10.1016/j.ijpx.2025.100362_bb0180) 2023; 14 Lin (10.1016/j.ijpx.2025.100362_bb0100) 2025; 18 Yang (10.1016/j.ijpx.2025.100362_bb0185) 2024; 374 Adeyi (10.1016/j.ijpx.2025.100362_bb0005) 2021; 25 Lv (10.1016/j.ijpx.2025.100362_bb0105) 2023; 635 Török (10.1016/j.ijpx.2025.100362_bb0165) 2021; 22 Wang (10.1016/j.ijpx.2025.100362_bb0170) 2021; 14 Sun (10.1016/j.ijpx.2025.100362_bb0155) 2022; 38 Kim (10.1016/j.ijpx.2025.100362_bb0085) 2022; 13 Moens (10.1016/j.ijpx.2025.100362_bb0125) 2022; 17 |
| References_xml | – volume: 15 start-page: 24494 year: 2023 end-page: 24503 ident: bb0205 article-title: Hierarchical hollow-TiO publication-title: ACS Appl. Mater. Interfaces – volume: 13 start-page: 2401869 year: 2024 end-page: 2401889 ident: bb0225 article-title: Tofacitinib citrate coordination-based dual-responsive/scavenge nanoplatform toward regulate colonic inflammatory microenvironment for relieving colitis publication-title: Adv. Healthc. Mater. – volume: 25 start-page: 100890 year: 2021 end-page: 100901 ident: bb0005 article-title: leaf fractions attenuated naje haje venom-induced cellular dysfunctions via modulation of Nrf publication-title: Biochem. Biophys. Rep. – volume: 73 start-page: 41 year: 2024 ident: bb0080 article-title: Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease publication-title: Gut – volume: 32 start-page: 2004647 year: 2020 end-page: 2004658 ident: bb0015 article-title: Colorectal tumor microenvironment-activated bio-decomposable and metabolizable Cu publication-title: Adv. Mater. – volume: 659 start-page: 124117 year: 2024 end-page: 124132 ident: bb0025 article-title: ROS-responsive nano-medicine for navigating autophagy to enhance targeted therapy of inflammatory bowel disease publication-title: Int. J. Pharm. – volume: 471 start-page: 144595 year: 2023 end-page: 144606 ident: bb0020 article-title: Therapy of spinal cord injury by zinc pyrogallol modified nanozyme via anti-inflammatory strategies publication-title: Chem. Eng. J. – volume: 19 start-page: 2207350 year: 2023 end-page: 2207370 ident: bb0065 article-title: Oral metal-free melanin nanozymes for natural and durable targeted treatment of inflammatory bowel disease (IBD) publication-title: Small (Weinheim an der Bergstrasse, Germany) – volume: 374 start-page: 140 year: 2024 end-page: 153 ident: bb0185 article-title: Modified montmorillonite armed probiotics with enhanced on-site mucus-depleted intestinal colonization and H publication-title: J. Control. Release – volume: 178 start-page: 363 year: 2021 end-page: 372 ident: bb0035 article-title: Protective effect of exopolysaccharide fraction from bacillus subtilis against dextran sulfate sodium-induced colitis through maintenance of intestinal barrier and suppression of inflammatory responses publication-title: Int. J. Biol. Macromol. – volume: 18 start-page: 67 year: 2025 end-page: 82 ident: bb0100 article-title: Therapeutic potential of publication-title: Pharmaceuticals-Base – volume: 22 start-page: 12729 year: 2021 end-page: 12745 ident: bb0165 article-title: Investigation of H publication-title: Int. J. Mol. Sci. – volume: 12 start-page: 272 year: 2019 end-page: 280 ident: bb0135 article-title: Mesalazine activates adenosine monophosphate-activated protein kinase: implication in the anti-inflammatory activity of this anti-colitic drug publication-title: Curr. Mol. Pharmacol. – volume: 11 start-page: 2466 year: 2023 end-page: 2471 ident: bb0130 article-title: Editorial: novel therapeutic approaches in inflammatory bowel diseases publication-title: Biomedicines – volume: 2023 start-page: 4613842 year: 2023 end-page: 4613848 ident: bb0010 article-title: Serum levels of proinflammatory biomarkers in military recruits with and without metabolic syndrome publication-title: Mediat. Inflamm. – volume: 14 start-page: 1260134 year: 2023 end-page: 1260154 ident: bb0060 article-title: Efficacy of extracellular vesicles as a cell-free therapy in colitis: a systematic review and meta-analysis of animal studies publication-title: Front. Pharmacol. – volume: 29 start-page: 536 year: 2021 end-page: 544 ident: bb0075 article-title: Hyaluronic acid increases anti-inflammatory efficacy of rectal 5-amino salicylic acid administration in a murine colitis model publication-title: Biomol. Ther. (Seoul) – volume: 30 start-page: S5 year: 2024 end-page: S18 ident: bb0040 article-title: Challenges in IBD research 2024: preclinical human IBD mechanisms publication-title: Inflamm. Bowel Dis. – volume: 15 start-page: 53198 year: 2023 end-page: 53216 ident: bb0220 article-title: Sequential rocket-mode bioactivating ticagrelor prodrug nanoplatform combining light-switchable diphtherin transgene system for breast cancer metastasis inhibition publication-title: ACS Appl. Mater. Interfaces – volume: 18 start-page: 2355 year: 2024 end-page: 2369 ident: bb0210 article-title: Engineered multifunctional zinc–organic framework-based aggregation-induced emission nanozyme for accelerating spinal cord injury recovery publication-title: ACS Nano – volume: 166 start-page: S56 year: 2024 end-page: S57 ident: bb0050 article-title: Trends in inflammatory bowel disease incidence and prevalence across epidemiologic stages: a global systematic review with meta-analysis publication-title: Gastroenterology – volume: 17 start-page: 0268551 year: 2022 end-page: 0268567 ident: bb0125 article-title: In vitro comparison of various antioxidants and flavonoids from rooibos as beta cell protectants against lipotoxicity and oxidative stress-induced cell death publication-title: PLoS One – volume: 14 start-page: 1143526 year: 2023 end-page: 1143539 ident: bb0180 article-title: Whole intestinal microbiota transplantation is more effective than fecal microbiota transplantation in reducing the susceptibility of DSS-induced germ-free mice colitis publication-title: Front. Immunol. – volume: 265 start-page: 118013 year: 2021 end-page: 118023 ident: bb0095 article-title: Magnetic microspheres based on pectin coated by chitosan towards smart drug release publication-title: Carbohydr. Polym. – volume: 107 start-page: 8 year: 2013 end-page: 15 ident: bb0150 article-title: Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) new complexes of 5-aminosalicylic acid: Spectroscopic, thermal characterization and biological activity studies publication-title: Spectrochim. Acta A – volume: 367 start-page: 167 year: 2024 end-page: 183 ident: bb0030 article-title: Spatiotemporally controlled exotoxin transgene system combined with multifunctional nanoparticles for breast cancer antimetastatic therapy publication-title: J. Control. Release – volume: 60 start-page: 2403 year: 2020 end-page: 2413 ident: bb0190 article-title: pH-responsive chitosan/sulfobutyl ether-β-cyclodextrin supramolecular nanoparticles for controlled release of sodium ferulate publication-title: Polym. Eng. Sci. – volume: 635 start-page: 122741 year: 2023 end-page: 122755 ident: bb0105 article-title: Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice publication-title: Int. J. Pharm. – volume: 32 start-page: 102099 year: 2024 end-page: 102112 ident: bb0145 article-title: Formulation, development and evaluation of hyaluronic acid-conjugated liposomal nanoparticles loaded with regorafenib and curcumin and their in vitro evaluation on colorectal cancer cell lines publication-title: Saudi Pharm. J. – volume: 14 start-page: 1701 year: 2021 end-page: 1716 ident: bb0170 article-title: Recent progress in the diagnosis and precise nanocarrier-mediated therapy of inflammatory bowel disease publication-title: J. Inflamm. Res. – volume: 29 start-page: 100 year: 2025 end-page: 112 ident: bb0055 article-title: Differential pathological changes in colon microenvironments in acute and chronic mouse models of inflammatory bowel disease publication-title: Anim. Cells Syst. – volume: 16 start-page: 24 year: 2025 end-page: 62 ident: bb0140 article-title: Biodegradable and stimuli-responsive nanomaterials for targeted drug delivery in autoimmune diseases publication-title: J. Funct. Biomater. – volume: 15 start-page: 26298 year: 2023 end-page: 26315 ident: bb0175 article-title: Colon-targeting angelica sinensis polysaccharide nanoparticles with dual responsiveness for alleviation of ulcerative colitis publication-title: ACS Appl. Mater. Interfaces – volume: 19 start-page: 100858 year: 2024 end-page: 100875 ident: bb0230 article-title: Hydrogen sulfide responsive nanoplatforms: novel gas responsive drug delivery carriers for biomedical applications publication-title: Asian J. Pharm. Sci. – volume: 21-23 year: 2024 ident: bb0200 article-title: The pectin metabolizing capacity of the human gut microbiota publication-title: Crit. Rev. Food Sci. Nutr. – volume: 20 start-page: 398 year: 2019 end-page: 414 ident: bb0070 article-title: Nanostructured chitosan-based biomaterials for sustained and colon-specific resveratrol release publication-title: Int. J. Mol. Sci. – volume: 20 start-page: 363 year: 2019 end-page: 378 ident: bb0090 article-title: Modern use of 5-aminosalicylic acid compounds for ulcerative colitis publication-title: Expert. Opin. Biol. Ther. – volume: 29 start-page: 700 year: 2023 end-page: 709 ident: bb0120 article-title: Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease publication-title: Nat. Med. – volume: 2018 start-page: 7918261 year: 2018 end-page: 7918268 ident: bb0045 article-title: Oxidative stress and effect of treatment on the oxidation product decomposition processes in IBD publication-title: Oxidative Med. Cell. Longev. – volume: 15 start-page: 1903473 year: 2019 end-page: 1903484 ident: bb0160 article-title: Surface plasmon resonance-enhanced photoacoustic imaging and photothermal therapy of endogenous H publication-title: Small (Weinheim an der Bergstrasse, Germany) – volume: 12 start-page: 117 year: 2019 end-page: 131 ident: bb0110 article-title: NOX publication-title: Mucosal Immunol. – volume: 38 start-page: 1621 year: 2022 end-page: 1630 ident: bb0155 article-title: Amino acid-mediated synthesis of the zif-8 nanozyme that reproduces both the zinc-coordinated active center and hydrophobic pocket of natural carbonic anhydrase publication-title: Langmuir – volume: 13 start-page: 817591 year: 2022 end-page: 817606 ident: bb0085 article-title: The probiotic strain bifidobacterium animalis ssp. Lactis hy8002 potentially improves the mucosal integrity of an altered intestinal microbial environment publication-title: Front. Microbiol. – volume: 11 start-page: 1828 year: 2020 end-page: 1838 ident: bb0195 article-title: Aminooxyacetic acid (AOAA) sensitizes colon cancer cells to oxaliplatin via exaggerating apoptosis induced by ROS publication-title: J. Cancer – volume: 32 start-page: 206 year: 2024 end-page: 221 ident: bb0115 article-title: A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment publication-title: Bioact. Mater. – volume: 177 start-page: 62 year: 2024 end-page: 76 ident: bb0215 article-title: Design of a Zn-based nanozyme injectable multifunctional hydrogel with ROS scavenging activity for myocardial infarction therapy publication-title: Acta Biomater. – volume: 178 start-page: 363 year: 2021 ident: 10.1016/j.ijpx.2025.100362_bb0035 article-title: Protective effect of exopolysaccharide fraction from bacillus subtilis against dextran sulfate sodium-induced colitis through maintenance of intestinal barrier and suppression of inflammatory responses publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2021.02.186 – volume: 32 start-page: 206 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0115 article-title: A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment publication-title: Bioact. Mater. – volume: 12 start-page: 272 year: 2019 ident: 10.1016/j.ijpx.2025.100362_bb0135 article-title: Mesalazine activates adenosine monophosphate-activated protein kinase: implication in the anti-inflammatory activity of this anti-colitic drug publication-title: Curr. Mol. Pharmacol. doi: 10.2174/1874467212666190308103448 – volume: 13 start-page: 2401869 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0225 article-title: Tofacitinib citrate coordination-based dual-responsive/scavenge nanoplatform toward regulate colonic inflammatory microenvironment for relieving colitis publication-title: Adv. Healthc. Mater. doi: 10.1002/adhm.202401869 – volume: 265 start-page: 118013 year: 2021 ident: 10.1016/j.ijpx.2025.100362_bb0095 article-title: Magnetic microspheres based on pectin coated by chitosan towards smart drug release publication-title: Carbohydr. Polym. doi: 10.1016/j.carbpol.2021.118013 – volume: 635 start-page: 122741 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0105 article-title: Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2023.122741 – volume: 19 start-page: 2207350 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0065 article-title: Oral metal-free melanin nanozymes for natural and durable targeted treatment of inflammatory bowel disease (IBD) publication-title: Small (Weinheim an der Bergstrasse, Germany) doi: 10.1002/smll.202207350 – volume: 29 start-page: 536 year: 2021 ident: 10.1016/j.ijpx.2025.100362_bb0075 article-title: Hyaluronic acid increases anti-inflammatory efficacy of rectal 5-amino salicylic acid administration in a murine colitis model publication-title: Biomol. Ther. (Seoul) doi: 10.4062/biomolther.2020.227 – volume: 18 start-page: 2355 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0210 article-title: Engineered multifunctional zinc–organic framework-based aggregation-induced emission nanozyme for accelerating spinal cord injury recovery publication-title: ACS Nano doi: 10.1021/acsnano.3c10541 – volume: 14 start-page: 1701 year: 2021 ident: 10.1016/j.ijpx.2025.100362_bb0170 article-title: Recent progress in the diagnosis and precise nanocarrier-mediated therapy of inflammatory bowel disease publication-title: J. Inflamm. Res. doi: 10.2147/JIR.S304101 – volume: 2023 start-page: 4613842 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0010 article-title: Serum levels of proinflammatory biomarkers in military recruits with and without metabolic syndrome publication-title: Mediat. Inflamm. doi: 10.1155/2023/4613842 – volume: 15 start-page: 24494 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0205 article-title: Hierarchical hollow-TiO2@CdS/ZnS hybrid for solar-driven CO2-selective conversion publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.3c03255 – volume: 2018 start-page: 7918261 year: 2018 ident: 10.1016/j.ijpx.2025.100362_bb0045 article-title: Oxidative stress and effect of treatment on the oxidation product decomposition processes in IBD publication-title: Oxidative Med. Cell. Longev. doi: 10.1155/2018/7918261 – volume: 15 start-page: 26298 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0175 article-title: Colon-targeting angelica sinensis polysaccharide nanoparticles with dual responsiveness for alleviation of ulcerative colitis publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.3c02128 – volume: 659 start-page: 124117 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0025 article-title: ROS-responsive nano-medicine for navigating autophagy to enhance targeted therapy of inflammatory bowel disease publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2024.124117 – volume: 32 start-page: 2004647 year: 2020 ident: 10.1016/j.ijpx.2025.100362_bb0015 article-title: Colorectal tumor microenvironment-activated bio-decomposable and metabolizable Cu2O@CaCO3 nanocomposites for synergistic oncotherapy publication-title: Adv. Mater. doi: 10.1002/adma.202004647 – volume: 12 start-page: 117 year: 2019 ident: 10.1016/j.ijpx.2025.100362_bb0110 article-title: NOX1-derived ROS drive the expression of lipocalin-2 in colonic epithelial cells in inflammatory conditions publication-title: Mucosal Immunol. doi: 10.1038/s41385-018-0086-4 – volume: 38 start-page: 1621 year: 2022 ident: 10.1016/j.ijpx.2025.100362_bb0155 article-title: Amino acid-mediated synthesis of the zif-8 nanozyme that reproduces both the zinc-coordinated active center and hydrophobic pocket of natural carbonic anhydrase publication-title: Langmuir doi: 10.1021/acs.langmuir.1c03118 – volume: 11 start-page: 2466 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0130 article-title: Editorial: novel therapeutic approaches in inflammatory bowel diseases publication-title: Biomedicines doi: 10.3390/biomedicines11092466 – volume: 20 start-page: 398 year: 2019 ident: 10.1016/j.ijpx.2025.100362_bb0070 article-title: Nanostructured chitosan-based biomaterials for sustained and colon-specific resveratrol release publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20020398 – volume: 107 start-page: 8 year: 2013 ident: 10.1016/j.ijpx.2025.100362_bb0150 article-title: Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) new complexes of 5-aminosalicylic acid: Spectroscopic, thermal characterization and biological activity studies publication-title: Spectrochim. Acta A doi: 10.1016/j.saa.2013.01.021 – volume: 177 start-page: 62 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0215 article-title: Design of a Zn-based nanozyme injectable multifunctional hydrogel with ROS scavenging activity for myocardial infarction therapy publication-title: Acta Biomater. doi: 10.1016/j.actbio.2024.01.015 – volume: 17 start-page: 0268551 year: 2022 ident: 10.1016/j.ijpx.2025.100362_bb0125 article-title: In vitro comparison of various antioxidants and flavonoids from rooibos as beta cell protectants against lipotoxicity and oxidative stress-induced cell death publication-title: PLoS One doi: 10.1371/journal.pone.0268551 – volume: 21-23 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0200 article-title: The pectin metabolizing capacity of the human gut microbiota publication-title: Crit. Rev. Food Sci. Nutr. – volume: 25 start-page: 100890 year: 2021 ident: 10.1016/j.ijpx.2025.100362_bb0005 article-title: Moringa oleifera leaf fractions attenuated naje haje venom-induced cellular dysfunctions via modulation of Nrf2 and inflammatory signalling pathways in rats publication-title: Biochem. Biophys. Rep. – volume: 14 start-page: 1143526 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0180 article-title: Whole intestinal microbiota transplantation is more effective than fecal microbiota transplantation in reducing the susceptibility of DSS-induced germ-free mice colitis publication-title: Front. Immunol. doi: 10.3389/fimmu.2023.1143526 – volume: 60 start-page: 2403 year: 2020 ident: 10.1016/j.ijpx.2025.100362_bb0190 article-title: pH-responsive chitosan/sulfobutyl ether-β-cyclodextrin supramolecular nanoparticles for controlled release of sodium ferulate publication-title: Polym. Eng. Sci. doi: 10.1002/pen.25479 – volume: 15 start-page: 53198 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0220 article-title: Sequential rocket-mode bioactivating ticagrelor prodrug nanoplatform combining light-switchable diphtherin transgene system for breast cancer metastasis inhibition publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.3c11594 – volume: 16 start-page: 24 year: 2025 ident: 10.1016/j.ijpx.2025.100362_bb0140 article-title: Biodegradable and stimuli-responsive nanomaterials for targeted drug delivery in autoimmune diseases publication-title: J. Funct. Biomater. doi: 10.3390/jfb16010024 – volume: 29 start-page: 700 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0120 article-title: Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease publication-title: Nat. Med. doi: 10.1038/s41591-023-02217-7 – volume: 32 start-page: 102099 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0145 article-title: Formulation, development and evaluation of hyaluronic acid-conjugated liposomal nanoparticles loaded with regorafenib and curcumin and their in vitro evaluation on colorectal cancer cell lines publication-title: Saudi Pharm. J. doi: 10.1016/j.jsps.2024.102099 – volume: 471 start-page: 144595 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0020 article-title: Therapy of spinal cord injury by zinc pyrogallol modified nanozyme via anti-inflammatory strategies publication-title: Chem. Eng. J. doi: 10.1016/j.cej.2023.144595 – volume: 14 start-page: 1260134 year: 2023 ident: 10.1016/j.ijpx.2025.100362_bb0060 article-title: Efficacy of extracellular vesicles as a cell-free therapy in colitis: a systematic review and meta-analysis of animal studies publication-title: Front. Pharmacol. doi: 10.3389/fphar.2023.1260134 – volume: 20 start-page: 363 year: 2019 ident: 10.1016/j.ijpx.2025.100362_bb0090 article-title: Modern use of 5-aminosalicylic acid compounds for ulcerative colitis publication-title: Expert. Opin. Biol. Ther. doi: 10.1080/14712598.2019.1666101 – volume: 29 start-page: 100 year: 2025 ident: 10.1016/j.ijpx.2025.100362_bb0055 article-title: Differential pathological changes in colon microenvironments in acute and chronic mouse models of inflammatory bowel disease publication-title: Anim. Cells Syst. doi: 10.1080/19768354.2025.2451408 – volume: 13 start-page: 817591 year: 2022 ident: 10.1016/j.ijpx.2025.100362_bb0085 article-title: The probiotic strain bifidobacterium animalis ssp. Lactis hy8002 potentially improves the mucosal integrity of an altered intestinal microbial environment publication-title: Front. Microbiol. doi: 10.3389/fmicb.2022.817591 – volume: 166 start-page: S56 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0050 article-title: Trends in inflammatory bowel disease incidence and prevalence across epidemiologic stages: a global systematic review with meta-analysis publication-title: Gastroenterology doi: 10.1053/j.gastro.2023.11.136 – volume: 374 start-page: 140 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0185 article-title: Modified montmorillonite armed probiotics with enhanced on-site mucus-depleted intestinal colonization and H2S scavenging for colitis treatment publication-title: J. Control. Release doi: 10.1016/j.jconrel.2024.07.071 – volume: 30 start-page: S5 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0040 article-title: Challenges in IBD research 2024: preclinical human IBD mechanisms publication-title: Inflamm. Bowel Dis. doi: 10.1093/ibd/izae081 – volume: 11 start-page: 1828 year: 2020 ident: 10.1016/j.ijpx.2025.100362_bb0195 article-title: Aminooxyacetic acid (AOAA) sensitizes colon cancer cells to oxaliplatin via exaggerating apoptosis induced by ROS publication-title: J. Cancer doi: 10.7150/jca.35375 – volume: 18 start-page: 67 year: 2025 ident: 10.1016/j.ijpx.2025.100362_bb0100 article-title: Therapeutic potential of Cajanus cajan (L.) millsp. Leaf extract in modulating gut microbiota and immune response for the treatment of inflammatory bowel disease publication-title: Pharmaceuticals-Base doi: 10.3390/ph18010067 – volume: 22 start-page: 12729 year: 2021 ident: 10.1016/j.ijpx.2025.100362_bb0165 article-title: Investigation of H2S donor treatment on neutrophil extracellular traps in experimental colitis publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms222312729 – volume: 367 start-page: 167 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0030 article-title: Spatiotemporally controlled exotoxin transgene system combined with multifunctional nanoparticles for breast cancer antimetastatic therapy publication-title: J. Control. Release doi: 10.1016/j.jconrel.2023.08.011 – volume: 15 start-page: 1903473 year: 2019 ident: 10.1016/j.ijpx.2025.100362_bb0160 article-title: Surface plasmon resonance-enhanced photoacoustic imaging and photothermal therapy of endogenous H2S-triggered Au@Cu2O publication-title: Small (Weinheim an der Bergstrasse, Germany) doi: 10.1002/smll.201903473 – volume: 19 start-page: 100858 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0230 article-title: Hydrogen sulfide responsive nanoplatforms: novel gas responsive drug delivery carriers for biomedical applications publication-title: Asian J. Pharm. Sci. – volume: 73 start-page: 41 year: 2024 ident: 10.1016/j.ijpx.2025.100362_bb0080 article-title: Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease publication-title: Gut doi: 10.1136/gutjnl-2024-332205 |
| SSID | ssj0002210389 |
| Score | 2.3105693 |
| Snippet | Characterized by weight loss, intestinal ulcerations, and diarrhea with blood or mucus, inflammatory bowel disease (IBD), which includes ulcerative colitis and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 100362 |
| SubjectTerms | 5-aminosalicylic acid Chitosan Hyaluronic acid Inflammatory bowel disease Pectin Research Paper Zinc coordination driven nanozyme |
| Title | Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment |
| URI | https://dx.doi.org/10.1016/j.ijpx.2025.100362 https://www.ncbi.nlm.nih.gov/pubmed/40747109 https://www.proquest.com/docview/3235390759 https://pubmed.ncbi.nlm.nih.gov/PMC12312066 https://doaj.org/article/7ac31cf7e9924191858d2da00cd9fb4e |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ja9wwFBYlp15KS7fpEhTorZjaWmzp2IaEEGjpoYHchKyFepiRh8mkWX5Nf2rfszzDuIX2UrB98C6_J73vSZ8_EfIuCogzVoZC8MgKIa0tFC99UXFhASW1QVnsh_z8pT67EOeX8nJvqi_khGV54PzhPjTW8crFJmjIFCC5UFJ55m1ZOq9jKwK2vhDz9pKp-SDqgsLfevxLJhO6uvnqFhJCJpEZwGs2iUSDYP8kIP0JOH_nTe4FotPH5NGIIOnH_OZPyIOQnpKfX7HhShCS6Hpkvf4INNnUrxZ2g8CUwobi7_g0k7-Dpz4skJVxR2Vhl13qryxqBMNKres8tcnT-y456nrIULvcbUj9GtvH4db3d8tAuwRLBL9aDuP1tO1vwoKO4z50x2N_Ri5OT74dnxXj5AuF4xpayVjpqJhjtW1lVJrFpvEArUT0nEdbM1f5OloAN6X3XjbOQ-0HcOkrp8DqoeTPyUHqU3hJoDQtA5u3Na-lsLxVrNEAVMoo4LJGqxl5vzWEWWWNDbMln80Nms2g2Uw224x8QlvtzkR97GEHeI0Zvcb8y2tmRG4tbUaokSEE3Kr768OPtm5hoB7i4IpNob--MpxxCR-ukXpGXmQ32b2iwFkKqhKOqIkDTcowPZK674PWNwCLChX3X_2PUr8mD7EsmY3zhhxs1tfhLWCqTXs4VJ_DobPrF9jdJoI |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pectinase+responsive+nanoplatform+for+oral+targeted+delivery+5-aminosalicylic+acid+and+zinc+coordination+driven+nanozyme+in+inflammatory+bowel+disease+treatment&rft.jtitle=International+journal+of+pharmaceutics%3A+X&rft.au=Lin%2C+Yiting&rft.au=Fang%2C+Siqi&rft.au=Chen%2C+Xinyi&rft.au=Li%2C+Xiang&rft.date=2025-12-01&rft.pub=Elsevier&rft.eissn=2590-1567&rft.volume=10&rft_id=info:doi/10.1016%2Fj.ijpx.2025.100362&rft.externalDocID=PMC12312066 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2590-1567&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2590-1567&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2590-1567&client=summon |